CORC

浏览/检索结果: 共6条,第1-6条 帮助

已选(0)清除 条数/页:   排序方式:
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Jiang-yan;  Qi, Shuang;  Wu, Hong;  Wang, Ao-li;  Liu, Qing-wang
收藏  |  浏览/下载:92/0  |  提交时间:2022/03/28
YES1amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer 期刊论文
BRITISH JOURNAL OF CANCER, 2020, 页码: 12
作者:  Wang, Lei;  Wang, Quanren;  Xu, Piaopiao;  Fu, Li;  Li, Yun
收藏  |  浏览/下载:15/0  |  提交时间:2020/12/24
DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp9O-Cdc37 interaction 期刊论文
CANCER LETTERS, 2018, 卷号: 434, 页码: 70-80
作者:  Chen, Xiangling;  Liu, Peng;  Wang, Quanren;  Li, Yun;  Fu, Li
收藏  |  浏览/下载:35/0  |  提交时间:2019/01/08
Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells 期刊论文
CANCER SCIENCE, 2017, 卷号: 108, 期号: 7, 页码: 1458-1468
作者:  Wang, Hongbin;  Wang, Wenqian;  Xu, Yongping;  Yang, Yong;  Chen, Xiaoyan
收藏  |  浏览/下载:31/0  |  提交时间:2019/01/08
Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody 期刊论文
ONCOTARGET, 2017, 卷号: 8, 期号: 26
作者:  Wang, Chao;  Wang, Lingfei;  Yu, Xiaojie;  Zhang, Yajun;  Meng, Yanchun
收藏  |  浏览/下载:7/0  |  提交时间:2019/12/05
Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody 期刊论文
ONCOTARGET, 2017, 卷号: 8, 期号: 26
作者:  Wang, Chao;  Wang, Lingfei;  Yu, Xiaojie;  Zhang, Yajun;  Meng, Yanchun
收藏  |  浏览/下载:10/0  |  提交时间:2019/12/06


©版权所有 ©2017 CSpace - Powered by CSpace